**Abstract**

**Background:** The current study was designed to demonstrate noninferiority of paliperidone palmitate 3-monthly formulation (PP3M) to PP 1-monthly formulation (PP1M) in Asian patients (China, Japan, Korea and Taiwan) with schizophrenia.

**Methods:** Eligible patients (18--70 years) entered 17-week, flexible-dose, open-label (OL) phase to receive PP1M. Stabilized patients were randomized (1:1) to receive fixed doses of PP1M or PP3M (175, 263, 350, or 525 mg eq.) in a 48-week, double-blind (DB) phase.

**Results:** Total 510 Asian patients were enrolled and dosed in OL phase (total population: n=1429; China: n=296, Japan: n=175, Korea: n=19, Taiwan: n=20); 344 Asian patients were randomized in DB phase (total population: PP3M=504; PP1M=512; China: PP3M=104; PP1M=106; Japan: PP3M=52; PP1M=56; Korea: PP3M=7; PP1M=5; Taiwan: PP3M=7; PP1M=7). The Kaplan-Meier estimate of the difference (95% CI) between the treatment groups (PP3M-PP1M) in percentages of patients who remained relapse free (primary efficacy endpoint) was similar in the larger 2 subgroups (China: 1.1% \[-6.1%; 8.3%\]; Japan: 5.1% \[-12.0%; 22.2%\]) and the total population (1.2% \[-2.7%; 5.1%\]); the lower bounds of the 95% CI for all subgroups were larger than the pre-specified non-inferiority margin of -15%. Incidences of treatment-emergent adverse events (TEAEs) during the OL phase (China: 198/296 \[66.9%\]; Japan: 132/175 \[75.4%\]) as well as DB phase (China: 149/210 \[71.0%\]; Japan: 99/108 \[91.7%\]) were higher in the larger 2 subgroups versus the total population (OL total population: 846/1429 \[59.2%\]; DB total population 682/1016 \[67.1%\]). Increased weight was the most frequent (≥20%) TEAE during the DB phase (PP3M vs. PP1M, China: 36.5% vs. 34.9%; Japan: 25.0% vs. 19.6%).

**Conclusions:** PP3M was non-inferior to PP1M and was similarly tolerable in both total population, and Asian patients with schizophrenia.
